Background & Aims: Multi-target stool DNA (mt-sDNA) is an established stool-based colorectal cancer screening test, yet long-term performance is not well-described. We evaluated follow-up colonoscopy rates & quality, neoplasia yield, and repeat-testing adherence over 10 years with an integrated screening program. Methods: We assembled a retrospective cohort of mt-sDNA tests (September 2014–July 2025) within a multi-site health system. A validated large-language-model pipeline extracted colonoscopy, pathology, and quality endpoints from free-text reports. Detection outcomes (adenoma detection rate, advanced neoplasia, modified advanced adenoma, sessile serrated lesion (SSL), and negative exams) were calculated among high-quality exams; adenocarcinoma, bowel preparation adequacy, and cecal intubation rate (CIR) used all screening exams. We assessed colonoscopy completion ≤1 year after positive mt-sDNA, follow-up colonoscopy findings, findings by time-to-colonoscopy, and adherence to repeat mt-sDNA after negative result. Results: Among 148,624 tests in 110,410 individuals, positivity was 13.6%. Of 19,506 positives, 65.1% completed colonoscopy within 12 months (median 82 days). Colonoscopy after a positive mt-sDNA had high yield: advanced adenoma diagnosis was 30.7%; adenocarcinoma was 1.3%. Of patients who had colonoscopy within 3 years of a negative mt-sDNA test, 45.2% had adenoma/serrated lesion, 9.3% had advanced adenoma and 0.5% had colon cancer. Adenoma detection rate after positive mt-sDNA (>50%) exceeded specialty society quality benchmarks and increased over time; Longer intervals (>6 months) to colonoscopy after a positive test were associated with higher advanced adenoma (trend P=0.001).After an initial negative mt-sDNA, only 35.3% were screened again by mt-sDNA testing within 3 years. Conclusions: Over a decade,mt-sDNA screening achieved high colonoscopy qualitybut revealed critical gaps in the care cascade. One-third of positive tests lacked timely follow-up and nearly two-thirds of negative tests were not repeated on schedule, suggesting opportunities for system-level interventions.
Adolescent-Centered Cannabis Messaging in Clinical Settings: Preliminary Qualitative Insights From Adolescents for Clinicians
Background and Objectives: We developed the Mayo Outpatient Precepting Evaluation Tool (MOPET) to assess and improve clinical teaching for family medicine residents. Given the scheduling challenges of peer evaluation, we sought to improve the MOPET’s usefulness by evaluating the reliability of self- and resident-reported teaching behaviors during clinical precepting compared to peer observation. Methods: Forty-eight half-day sessions in a family medicine residency clinic were assessed with parallel observer, preceptor, and resident MOPET forms. Interrater reliability was calculated using the κ (kappa) statistic. Results: Residents reported that preceptors used 14 of 20 teaching behaviors more often than observers. Observers and preceptors significantly agreed on the use of five teaching behaviors, while residents agreed with observers on two teaching behaviors. Conclusions: Although self-assessment and resident-based feedback of preceptor teaching behavior may improve practicality, they are less reliable compared to direct peer observation with the validated MOPET.
A community participatory approach to enhancing capacity in patient-centered alcohol research: Bridging translational science and empowering women
Abstract Alcohol misuse among women has risen compared to men. Women experience barriers to engaging in patient-centered comparative effectiveness research (CER) that, in turn, limits the evidence base for addressing alcohol misuse in this population. In this manuscript, we describe WomenWise, a community-partnered project and outline how we co-developed community focused CER training curriculum and collaboratively planned future partnered learning sessions (PLSs) with Community Advisory Board (CAB) feedback. Through this approach we aim to empower women to contribute to future patient-centered CER and enhance the stakeholder capacity for future patient-centered research.